[Cefoperazone: microbiological, kinetic and clinical studies].
In vitro cefoperazone proved more active against the tested gram-negative bacteria than either piperacillin or mezlocillin. When administered in 1 g venous bolus the antibiotic achieved high plasmatic concentrations that were still adequate after 8 hours. 33.2% was excreted by the kidneys and a considerable amount by the biliary way. Cefoperazone produced a clinical cure in 35/36 patients (97.22%). A disulfiram-like effect was noted in 18.18%.
D001424:Bacterial Infections / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D002438:Cefoperazone / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D004886:Erysipelas / Q000188:drug therapy; D006801:Humans; D007700:Kinetics; D008802:Mezlocillin / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D014069:Tonsillitis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002438:Cefoperazone; D008802:Mezlocillin; D010878:Piperacillin
Cefoperazone: ricerca microbiologica, cinetica e clinica.